<?xml version='1.0' encoding='utf-8'?>
<document id="24487120"><sentence text="6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects."><entity charOffset="0-18" id="DDI-PubMed.24487120.s1.e0" text="6β-Hydroxycortisol" /></sentence><sentence text="6β-Hydroxycortisol (6β-OHF) is a substrate of the organic anion transporter 3 (OAT3) and the multidrug and toxin extrusion proteins MATE1 and MATE-2K in the corresponding cDNA-transfected cells"><entity charOffset="0-18" id="DDI-PubMed.24487120.s2.e0" text="6β-Hydroxycortisol" /></sentence><sentence text=" This study aimed to examine the contribution of OAT3 and MATEs to the urinary excretion of 6β-OHF in humans using the appropriate in vivo inhibitors, probenecid and pyrimethamine, for OAT3 and MATEs, respectively"><entity charOffset="92-98" id="DDI-PubMed.24487120.s3.e0" text="6β-OHF" /><entity charOffset="151-161" id="DDI-PubMed.24487120.s3.e1" text="probenecid" /><entity charOffset="166-179" id="DDI-PubMed.24487120.s3.e2" text="pyrimethamine" /><pair ddi="false" e1="DDI-PubMed.24487120.s3.e0" e2="DDI-PubMed.24487120.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24487120.s3.e0" e2="DDI-PubMed.24487120.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24487120.s3.e0" e2="DDI-PubMed.24487120.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24487120.s3.e1" e2="DDI-PubMed.24487120.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24487120.s3.e1" e2="DDI-PubMed.24487120.s3.e2" /></sentence><sentence text=" Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18"><entity charOffset="64-70" id="DDI-PubMed.24487120.s4.e0" text="6β-OHF" /><entity charOffset="82-88" id="DDI-PubMed.24487120.s4.e1" text="6β-OHF" /><pair ddi="false" e1="DDI-PubMed.24487120.s4.e0" e2="DDI-PubMed.24487120.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24487120.s4.e0" e2="DDI-PubMed.24487120.s4.e1" /></sentence><sentence text="1 ± 1" /><sentence text="5 versus 7" /><sentence text="60 ± 1" /><sentence text="8 ml/min/kg)" /><sentence text=" 6β-OHF uptake by human kidney slices was inhibited significantly by probenecid to 20-45% of the control values and partly by 1-methyl-4-phenylpyridinium"><entity charOffset="1-7" id="DDI-PubMed.24487120.s9.e0" text="6β-OHF" /><entity charOffset="126-153" id="DDI-PubMed.24487120.s9.e1" text="1-methyl-4-phenylpyridinium" /><pair ddi="false" e1="DDI-PubMed.24487120.s9.e0" e2="DDI-PubMed.24487120.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24487120.s9.e0" e2="DDI-PubMed.24487120.s9.e1" /></sentence><sentence text=" 6β-OHF plasma concentration and the amount of 6β-OHF excreted into the urine (X(6β-OHF)) were measured in healthy subjects enrolled in drug-drug interaction studies of benzylpenicillin alone or with probenecid (study 1), adefovir alone or with probenecid (study 2), and metformin alone or with pyrimethamine (study 3)"><entity charOffset="1-7" id="DDI-PubMed.24487120.s10.e0" text="6β-OHF" /><entity charOffset="47-53" id="DDI-PubMed.24487120.s10.e1" text="6β-OHF" /><entity charOffset="169-185" id="DDI-PubMed.24487120.s10.e2" text="benzylpenicillin" /><entity charOffset="200-210" id="DDI-PubMed.24487120.s10.e3" text="probenecid" /><entity charOffset="222-230" id="DDI-PubMed.24487120.s10.e4" text="adefovir" /><entity charOffset="245-255" id="DDI-PubMed.24487120.s10.e5" text="probenecid" /><entity charOffset="271-280" id="DDI-PubMed.24487120.s10.e6" text="metformin" /><entity charOffset="295-308" id="DDI-PubMed.24487120.s10.e7" text="pyrimethamine" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e0" e2="DDI-PubMed.24487120.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e0" e2="DDI-PubMed.24487120.s10.e1" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e0" e2="DDI-PubMed.24487120.s10.e2" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e0" e2="DDI-PubMed.24487120.s10.e3" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e0" e2="DDI-PubMed.24487120.s10.e4" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e0" e2="DDI-PubMed.24487120.s10.e5" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e0" e2="DDI-PubMed.24487120.s10.e6" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e0" e2="DDI-PubMed.24487120.s10.e7" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e1" e2="DDI-PubMed.24487120.s10.e1" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e1" e2="DDI-PubMed.24487120.s10.e2" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e1" e2="DDI-PubMed.24487120.s10.e3" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e1" e2="DDI-PubMed.24487120.s10.e4" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e1" e2="DDI-PubMed.24487120.s10.e5" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e1" e2="DDI-PubMed.24487120.s10.e6" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e1" e2="DDI-PubMed.24487120.s10.e7" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e2" e2="DDI-PubMed.24487120.s10.e2" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e2" e2="DDI-PubMed.24487120.s10.e3" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e2" e2="DDI-PubMed.24487120.s10.e4" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e2" e2="DDI-PubMed.24487120.s10.e5" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e2" e2="DDI-PubMed.24487120.s10.e6" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e2" e2="DDI-PubMed.24487120.s10.e7" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e3" e2="DDI-PubMed.24487120.s10.e3" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e3" e2="DDI-PubMed.24487120.s10.e4" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e3" e2="DDI-PubMed.24487120.s10.e5" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e3" e2="DDI-PubMed.24487120.s10.e6" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e3" e2="DDI-PubMed.24487120.s10.e7" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e4" e2="DDI-PubMed.24487120.s10.e4" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e4" e2="DDI-PubMed.24487120.s10.e5" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e4" e2="DDI-PubMed.24487120.s10.e6" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e4" e2="DDI-PubMed.24487120.s10.e7" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e5" e2="DDI-PubMed.24487120.s10.e5" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e5" e2="DDI-PubMed.24487120.s10.e6" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e5" e2="DDI-PubMed.24487120.s10.e7" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e6" e2="DDI-PubMed.24487120.s10.e6" /><pair ddi="false" e1="DDI-PubMed.24487120.s10.e6" e2="DDI-PubMed.24487120.s10.e7" /></sentence><sentence text=" Probenecid treatment caused a 57 and 76% increase in the area under the plasma concentration-time curve for 6β-OHF (AUC(6β-OHF)) in studies 1 and 2, respectively, but did not affect X(6β-OHF)"><entity charOffset="1-11" id="DDI-PubMed.24487120.s11.e0" text="Probenecid" /><entity charOffset="109-115" id="DDI-PubMed.24487120.s11.e1" text="6β-OHF" /><pair ddi="false" e1="DDI-PubMed.24487120.s11.e0" e2="DDI-PubMed.24487120.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24487120.s11.e0" e2="DDI-PubMed.24487120.s11.e1" /></sentence><sentence text=" Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively"><entity charOffset="25-31" id="DDI-PubMed.24487120.s12.e0" text="6β-OHF" /></sentence><sentence text=" By contrast, neither AUC(6β-OHF) nor CL(renal, 6β-OHF) was significantly altered by pyrimethamine administration"><entity charOffset="22-33" id="DDI-PubMed.24487120.s13.e0" text="AUC(6β-OHF)" /><entity charOffset="48-54" id="DDI-PubMed.24487120.s13.e1" text="6β-OHF" /><entity charOffset="85-98" id="DDI-PubMed.24487120.s13.e2" text="pyrimethamine" /><pair ddi="false" e1="DDI-PubMed.24487120.s13.e0" e2="DDI-PubMed.24487120.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24487120.s13.e0" e2="DDI-PubMed.24487120.s13.e1" /><pair ddi="false" e1="DDI-PubMed.24487120.s13.e0" e2="DDI-PubMed.24487120.s13.e2" /><pair ddi="false" e1="DDI-PubMed.24487120.s13.e1" e2="DDI-PubMed.24487120.s13.e1" /><pair ddi="false" e1="DDI-PubMed.24487120.s13.e1" e2="DDI-PubMed.24487120.s13.e2" /></sentence><sentence text=" Taken together, these data suggest that OAT3 plays a significant role in the urinary excretion of 6β-OHF, and that 6β-OHF can be used to investigate the perpetrators of the pharmacokinetic drug interactions involving OAT3 in humans"><entity charOffset="99-105" id="DDI-PubMed.24487120.s14.e0" text="6β-OHF" /><entity charOffset="116-122" id="DDI-PubMed.24487120.s14.e1" text="6β-OHF" /><pair ddi="false" e1="DDI-PubMed.24487120.s14.e0" e2="DDI-PubMed.24487120.s14.e0" /><pair ddi="false" e1="DDI-PubMed.24487120.s14.e0" e2="DDI-PubMed.24487120.s14.e1" /></sentence><sentence text="" /></document>